PTN participant classification
| Age (years) | Sex | Side of pain | Diary pain intensity (VAS) | Diary pain variability (SD) | Pain duration (months) | Current medication use | |
|---|---|---|---|---|---|---|---|
| 1 | 29 | F | Left | 5.3 | 1.5 | 49 | - |
| 2 | 45 | M | Left | 3.1 | 0.4 | 21 | - |
| 3 | 35 | M | Right | 1.5 | 0.7 | 96 | PEA |
| 4 | 78 | F | Left | 1.9 | 0.7 | 314 | Paracetamol, Ostelin, Pristiq, Somac |
| 5 | 47 | F | Right | 2.1 | 0.4 | 13 | PEA |
| 6 | 34 | M | Right | 3.7 | 1.7 | 10 | PEA, Mersyndol |
| 7 | 66 | M | Left | 3.9 | 0.6 | 48 | - |
| 8 | 44 | F | Right | - | - | 5 | Valium, Panadeine Forte |
| 9 | 47 | F | Right | 4.1 | 1.6 | 7 | - |
| 10 | 44 | F | Left | 8.1 | 0.4 | 75 | PEA |
| 11 | 46 | F | Left | 7.5 | 2.5 | 27 | Endep |
| 12 | 28 | F | Right | 5.8 | 0.3 | 52 | - |
| 13 | 25 | M | Right | 4.5 | 1.7 | 8 | Panadeine Forte |
| 14 | 69 | F | Right | 3.9 | 0.4 | 259 | Endep, Lyrica, Oroxine, Crestor, Effexor, folic acid, prednisone |
| 15 | 45 | F | Bilateral | 2.8 | 2.8 | 24 | Duloxetine |
| 16 | 66 | M | Right | 1.8 | 0.7 | 81 | Endep |
| 17 | 36 | F | Left | 1.9 | 0.6 | 37 | PEA |
| 18 | 40 | F | Left | 5.8 | 0.3 | 33 | - |
| 19 | 58 | F | Left | 4.0 | 0.4 | 11 | Namipril, Zoloft, Panadol, PEA |
| 20 | 35 | M | Left | 4.2 | 0.7 | 60 | - |
| 21 | 67 | M | Bilateral | 2.0 | 0.9 | 96 | Endep |
| 22 | 51 | F | Left | 1.5 | 0.3 | 13 | Mobic, PEA |
| 23 | 35 | F | Right | 3.4 | 1.0 | 15 | Amitriptyline |
| 24 | 64 | F | Bilateral | - | - | 144 | - |
Participants 1–13 were placed in the fluctuating pain group, and Participants 14–23 were placed in the stable pain group. PEA, palmitoylethanolamide; VAS, visual analog scale; SD, standard deviation.